Viewing
|Articles|March 6, 2007

siRNA candidate enters the clinic

SR Pharma has launched a Phase I clinical trial of RTP-801i.

SR Pharma has launched a Phase I clinical trial of RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from Atugen AG, a subsidiary of SR Pharma.

RTP-801i is based on Atugen's proprietary siRNA technology that modifies the expression of one specific gene target involved in the progression of age-related macular degeneration (AMD).

Pfizer, who licensed the product in September of last year, is funding the trial.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe

Latest CME